Once the drug has been approved, it will now be difficult to find people who may benefit. 85 percent of patients will not be screened if they aren’t related to someone with diabetes.

The JDRF a A nonprofit organization that advocates for people with disabilities Type 1 diabetes and supports research, which, along with the N.I.H., funded the trial that led to the drug’s approval, wants antibody screening tests to become part of routine pediatric care.

“Most families say diagnosis is a bolt out of the blue,” Aaron Kowalski is the chief executive officer of JDRF. He said that most patients are not very well when they are first diagnosed.

It has also conducted blood tests in Germany and Colorado to check for antibodies. And it has offered an at-home (*1*) people can order, underwritten by the foundation. Dr. Kowalski explained that, “we want pediatric offices to do it.”

He said that testing also provides another option. While antibodies that signal an immune attack are common in children as young as five or six years of age, most people do not get diabetes until their teens.

He stated that he hopes to be able to treat patients sooner, once the antibodies are available. The F.D.A. and Clinicians. Previously, doctors and the F.D.A. had objected to treating before the disease was clearly under control. “How can you give an immunotherapy if they are normal?” Dr. Kowalski spoke.

However, he stated that antibodies tell the truth. a Different story.

“They do have diabetes,” He said that, but not according to the traditional definition of the disease. “It just hasn’t unmasked itself yet. We need to help them save their beta cells,” The pancreas’ insulin-secreting cells.